What is Imagene AI?
Imagene AI operates at the intersection of artificial intelligence and clinical diagnostics, providing AI-based molecular testing for cancer. By analyzing histological data, the company enables clinicians to deliver highly personalized therapy, effectively bridging the gap between raw tissue imaging and actionable genomic insights. This technological framework positions Imagene AI as a critical player in the digital health ecosystem, where the demand for rapid, non-invasive diagnostic tools is accelerating. The company's market position is bolstered by its ability to integrate seamlessly into existing pathology workflows, thereby enhancing diagnostic accuracy and patient outcomes in oncology care.
How much funding has Imagene AI raised?
Imagene AI has raised a total of $44.5M across 3 funding rounds:
Angel/Seed
$3M
Series A
$18.5M
Series B
$23M
Angel/Seed (2022): $3M with participation from Blumberg Capital Partners
Series A (2022): $18.5M led by Eyal Gura, Dr. David Agus, and Larry Ellison
Series B (2025): $23M supported by Aguras Pathology Investments and Larry Ellison
Key Investors in Imagene AI
Larry Ellison
A prominent technology visionary and investor with a deep interest in the intersection of data science and healthcare innovation.
Dr. David Agus
A renowned physician and researcher specializing in oncology and the application of advanced technology to improve patient longevity.
Aguras Pathology Investments
A specialized investment vehicle focused on the advancement of diagnostic pathology and molecular testing infrastructure.
What's next for Imagene AI?
With the successful closure of this latest financing round, Imagene AI is poised to scale its operational footprint and expand its clinical validation studies. The strategic focus will likely shift toward deepening its diagnostic capabilities and pursuing broader regulatory approvals to facilitate global market entry. As the company transitions from a scaling enterprise to a mature diagnostic platform, the focus remains on refining its AI algorithms to cover a wider spectrum of oncological conditions. Investors are closely monitoring the firm's ability to translate its technological edge into widespread clinical adoption, which will be the primary driver for future growth and potential market consolidation in the precision medicine space.
See full Imagene AI company page
